Showing 1251-1260 of 7022 results for "".
The State of AI in Dermatology
https://practicaldermatology.com/issues/january-february-2025/the-state-of-ai-in-dermatology/32927/The term “artificial intelligence” (AI) has been inescapable since OpenAI released ChatGPT to the public in November 2022.Starting a Systemic Therapy in Atopic Dermatitis or Psoriasis
https://practicaldermatology.com/series/pa-perspectives/Starting-a-Systemic-Therapy-in-Atopic-Dermatitis-or-Psoriasis/26644/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, discusses how to talk to patients about starting a systemic therapy in atopic dermatitis or psoriasis; how to keep the conversation to 7 minutes; and the importance of“Ask Me Anything” Mentorship Session: Dr. Natasha Mesinkovska on Academia, Alopecia Areata, and More
https://practicaldermatology.com/youngmd-connect/on-demand-virtual-sessions/ask-me-anything-mentorship-session-dr-natasha-mesinkovska-on-academia-alopecia-areata-and-more/48814/Natasha Atanaskova Mesinkovsa, MD, PhD, vice chair for clinical research in the UC Irvine School of Medicine's Department of Dermatology, discusses how she navigated her unique career path, how she balances her various responsibilities now, and more in an "Ask Me Anything" mentorship session.DermwireTV: Rinvoq Approved for Pediatric Psoriatic Arthritis; J&J Acquires Novel AD Candidate
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-rinvoq-approved-for-pediatric-psoriatic-arthritis/26269/In this week's DermwireTV, the FDA approves Rinvoq for pediatric psoriatic arthritis; Johnson & Johnson acquires an AD candidate for $1.25 billion; and the president of Acclaro Medical discusses the latest FDA clearance of its Ultraclear Laser.PDT: Patient Profiles for a Practice-changing Treatment
https://practicaldermatology.com/series/pdt-in-practice/pdt-patient-profiles-for-a-practice-changing-treatment/20186/Who's the ideal candidate for PDT? Other options, limitations? The advances in PDT both doctors and patients would like to see are described by Corey Hartman, MD, who shares his experiences and relates how PDT has improved his practice.Tips for Success with Fillers
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/tips-for-success-with-fillers/20149/Heidi Waldorf, MD offers tips for getting the best results possible with fillers. From how to evaluate what patients need to considering shapes and proportions, she offers hands-on advice to help achieve optimal outcomes. Plus, she discusses the importance of managing patient expectations.Identifying SCC Risk
https://practicaldermatology.com/topics/skin-cancer-photoprotection/identifying-scc-risk/20144/Sherrif Ibrahim, MD discusses the challenges of managing squamous cell carcinoma (SCC). Great steps have been made in clinical, pathological staging systems, but Dr. Ibrahim says it’s still difficult to determine what to do with borderline cases. He talks about the need to determine frequency and inChoosing the Right Resurfacing Treatment
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/choosing-the-right-resurfacing-treatment/20141/Joel L. Cohen, MD discusses how he assesses the area around the mouth to determine the best resurfacing treatment option. From fine lines and etching around the mouth to issues with pigmentation and redness, he says there are many options from low-downtime treatments to full-field erbium treatments.DermWireTV: Zoryve Approved; New SDPA President; Project Determi-Nation; Stelara for Pediatric PsA
https://practicaldermatology.com/topics/psoriasis/dermwiretv-zoryve-approved-new-sdpa-president-project-determi-nation-stelara-for-pediatric-psa/20115/FDA has approved Zoryve from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The novel formulation of roflumilast cream 0.3% is indicated for once-daily application. Stelara (ustekinumab) from Janssen is now approveEBD Insights
https://practicaldermatology.com/conferences/maui-derm-2022/ebd-insights/20049/There are a number of new and reliable energy-based devices available. Michael H. Gold, MD discusses tried-and-true technologies as well as new and innovative devices that offer efficacious options on the market for a variety of dermatologic needs.